Clinical Trial · NCT03168737

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Overview

This early phase I trial studies how well 18F-fluoroazomycin arabinoside positron emission tomography (PET)-computed tomography (CT) works in diagnosing solid tumors. Using 18F-fluoroazomycin arabinoside with PET-CT may help doctors plan better treatment for patients with solid tumors. 18F-fluoroazomycin arabinoside may help to show how much oxygen is present in a tumor during a PET-CT scan.

Sponsor

MD Anderson Cancer Center

Phase

Phase 1

Contacts

Franklin C Wong (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03168737

Drug / Compound

fluoroazomycin arabinoside

Isotope(s):

Target(s):

Hypoxia

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients who are not expected to receive cancer therapy before imaging sessions are completed.
Patient must have a solid tumor with a short-axis greater than or equal to 1 cm (by CT, magnetic resonance imaging \[MRI\], ultrasonography or mammography) to allow reliable PET imaging.
Patients with histopathologic diagnosis of a solid tumor. All solid tumors will be considered, but patients with breast, pancreas, and colorectal masses will be prioritized.
A patient who has not received systemic or loco-regional treatment of the tumor within the last month.

Exclusion

Patients with a body weight of 400 pounds or more, or a body mass index (BMI) which precludes their entry into the bore of the PET/CT scanner, because the findings will probably be compromised in image quality with CT, PET/CT and MRI.